gemfibrozil has been researched along with Disease Models, Animal in 19 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemfibrozil (GFZ) is a medication of the fibrate category with agonistic effects on peroxisome proliferator-activated receptor-α (PPAR-α) and is effective for hypertriglyceridemia and mixed dyslipidemia." | 5.91 | Gemfibrozil, a lipid-lowering drug, improves hepatorenal damages in a mouse model of aging. ( Fatemi, I; Giménez-Llort, L; Hakimizadeh, E; Hassanipour, M; Soltani, A; Tadayon, S; Zamanian, MY, 2023) |
| "Cardiac hypertrophy was induced by partial abdominal aortic constriction in rats and they survived for 4 weeks." | 5.42 | Ameliorative role of gemfibrozil against partial abdominal aortic constriction-induced cardiac hypertrophy in rats. ( Krishan, P; Singh, AP; Singh, R, 2015) |
| "Gemfibrozil (GFZ) is a medication of the fibrate category with agonistic effects on peroxisome proliferator-activated receptor-α (PPAR-α) and is effective for hypertriglyceridemia and mixed dyslipidemia." | 1.91 | Gemfibrozil, a lipid-lowering drug, improves hepatorenal damages in a mouse model of aging. ( Fatemi, I; Giménez-Llort, L; Hakimizadeh, E; Hassanipour, M; Soltani, A; Tadayon, S; Zamanian, MY, 2023) |
| "Rhabdomyolysis is characterized by elevation of plasma creatine phosphokinase (CPK) level, and multiple organ disorders, especially renal failure, as well as approximately 50% of acquired rhabdomyolysis are caused by pharmaceuticals." | 1.51 | Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate. ( Akai, S; Matsubara, A; Oda, S; Watanabe, K; Yokoi, T, 2019) |
| "Cardiac hypertrophy was induced by partial abdominal aortic constriction in rats and they survived for 4 weeks." | 1.42 | Ameliorative role of gemfibrozil against partial abdominal aortic constriction-induced cardiac hypertrophy in rats. ( Krishan, P; Singh, AP; Singh, R, 2015) |
| "Andrographolide (1) has been identified as one of the active constituents against atherosclerosis." | 1.39 | Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity. ( Bhatia, G; Pandeti, S; Shukla, A; Sonkar, R; Tadigoppula, N, 2013) |
| " Multivariable data analysis was employed to explore the relationship between pharmacokinetic parameters and myotoxicity markers." | 1.35 | Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties. ( Dai, R; Gonzalez, FJ; Liu, A; Sun, H; Wei, X; Xie, S, 2009) |
| "Gemfibrozil has been shown to have beneficial effects in the primary and secondary prevention of atherosclerosis." | 1.31 | Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia. ( Alfón, J; Badimon, L; Berrozpe, M; Royo, T, 2000) |
| "Experimental hyperlipidemia was induced in ddY, C57BL, BALB and ICR strain mice and in Wistar rats." | 1.27 | [Strains and species differences in experimental hyperlipidemia]. ( Hirai, Y; Kawakami, M; Koyama, S; Mishima, Y; Mizutani, A; Morishita, S; Saito, T, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 4 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Idrees, GA | 1 |
| Abuo-Rahma, Gel-D | 1 |
| Aly, OM | 1 |
| Radwan, MF | 1 |
| Pandeti, S | 1 |
| Sonkar, R | 1 |
| Shukla, A | 1 |
| Bhatia, G | 1 |
| Tadigoppula, N | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Kress, BJ | 1 |
| Kim, DH | 1 |
| Mayo, JR | 1 |
| Farris, JT | 1 |
| Heck, B | 1 |
| Sarver, JG | 1 |
| Andy, D | 1 |
| Trendel, JA | 1 |
| Heck, BE | 1 |
| Erhardt, PW | 1 |
| Hakimizadeh, E | 1 |
| Tadayon, S | 1 |
| Zamanian, MY | 1 |
| Soltani, A | 1 |
| Giménez-Llort, L | 1 |
| Hassanipour, M | 1 |
| Fatemi, I | 1 |
| Zabihi, M | 1 |
| Askarian, F | 1 |
| Hekmatimoghaddam, S | 1 |
| Zabihi, MS | 1 |
| Vahidi, F | 1 |
| Behiry, S | 1 |
| Rabie, A | 1 |
| Kora, M | 1 |
| Ismail, W | 1 |
| Sabry, D | 1 |
| Zahran, A | 1 |
| Watanabe, K | 1 |
| Oda, S | 1 |
| Matsubara, A | 1 |
| Akai, S | 1 |
| Yokoi, T | 1 |
| Arya, N | 1 |
| Munde, MK | 1 |
| Dwivedi, J | 1 |
| Jagdale, AY | 1 |
| Jain, KS | 1 |
| Singh, AP | 1 |
| Singh, R | 1 |
| Krishan, P | 1 |
| Rai, H | 1 |
| Dhaneshwar, SS | 1 |
| Bodas, M | 1 |
| Patel, N | 1 |
| Silverberg, D | 1 |
| Walworth, K | 1 |
| Vij, N | 1 |
| Liu, A | 1 |
| Xie, S | 1 |
| Sun, H | 1 |
| Gonzalez, FJ | 1 |
| Wei, X | 1 |
| Dai, R | 1 |
| Maiguma, T | 1 |
| Fujisaki, K | 1 |
| Itoh, Y | 1 |
| Makino, K | 1 |
| Teshima, D | 1 |
| Takahashi-Yanaga, F | 1 |
| Sasaguri, T | 1 |
| Oishi, R | 1 |
| Rizvi, F | 1 |
| Iftikhar, M | 1 |
| George, JP | 1 |
| Calkin, AC | 1 |
| Giunti, S | 1 |
| Jandeleit-Dahm, KA | 1 |
| Allen, TJ | 1 |
| Cooper, ME | 1 |
| Thomas, MC | 1 |
| Royo, T | 1 |
| Alfón, J | 1 |
| Berrozpe, M | 1 |
| Badimon, L | 1 |
| Olivier, P | 1 |
| Plancke, MO | 1 |
| Marzin, D | 1 |
| Clavey, V | 1 |
| Sauzieres, J | 1 |
| Fruchart, JC | 1 |
| Morishita, S | 1 |
| Saito, T | 1 |
| Mishima, Y | 1 |
| Mizutani, A | 1 |
| Hirai, Y | 1 |
| Koyama, S | 1 |
| Kawakami, M | 1 |
19 other studies available for gemfibrozil and Disease Models, Animal
| Article | Year |
|---|---|
Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Drug Design; Gemfibrozil; Hypoli | 2009 |
Synthesis of new andrographolide derivatives and evaluation of their antidyslipidemic, LDL-oxidation and antioxidant activity.
Topics: Animals; Antioxidants; Disease Models, Animal; Diterpenes; Humans; Hyperlipidemias; Hypolipidemic Ag | 2013 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Drug Design; Female; Femur; Humans; Mesenchym | 2021 |
Gemfibrozil, a lipid-lowering drug, improves hepatorenal damages in a mouse model of aging.
Topics: Aging; Animals; Antioxidants; Disease Models, Animal; Gemfibrozil; Hypolipidemic Agents; Liver; Male | 2023 |
Combination of atorvastatin and gemfibrozil plus physical activity: an animal model of statin/fibrate-induced myopathy.
Topics: Animals; Atorvastatin; Disease Models, Animal; Fibric Acids; Gemfibrozil; Hydroxymethylglutaryl-CoA | 2021 |
Effect of combination sildenafil and gemfibrozil on cisplatin-induced nephrotoxicity; role of heme oxygenase-1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Cisplatin; Creatinine; Disease Models, Animal | 2018 |
Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate.
Topics: Animals; Caspase 3; Caspase 7; Disease Models, Animal; Drug Interactions; Female; Fibric Acids; Gemf | 2019 |
Design, synthesis, and antihyperlipidemic evaluation of novel 2-[1-(substitutedphenyl)-4-oxo-azetidin-2-yl]-5,6-disubstitutedthieno[2,3-d]pyrimidin-4(3H)-ones.
Topics: Animals; Azetidines; Biomarkers; Cholesterol; Disease Models, Animal; Drug Design; Gemfibrozil; Hype | 2013 |
Ameliorative role of gemfibrozil against partial abdominal aortic constriction-induced cardiac hypertrophy in rats.
Topics: Animals; Aorta, Abdominal; Cardiomegaly; Constriction; Disease Models, Animal; Gemfibrozil; Heart; H | 2015 |
Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study.
Topics: Amides; Animals; Cholesterol, HDL; Disease Models, Animal; Ethanolamine; Gemfibrozil; Humans; Hyperl | 2015 |
Master Autophagy Regulator Transcription Factor EB Regulates Cigarette Smoke-Induced Autophagy Impairment and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis.
Topics: Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line; Cell Nuc | 2017 |
Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gemfibrozil; Macaca fasci | 2009 |
Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
Topics: Bezafibrate; Clofibrate; Clofibric Acid; Disease Models, Animal; Drug Synergism; Fenofibrate; Fibric | 2003 |
Beneficial effects of fish liver preparations of sea bass (Lates calcarifer) versus gemfibrozil in high fat diet-induced lipid-intolerant rats.
Topics: Animals; Bass; Cholesterol, LDL; Cholesterol, VLDL; Disease Models, Animal; Feces; Fish Oils; Gemfib | 2003 |
PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Topics: Animals; Apolipoproteins E; Collagen Type IV; Creatinine; Diabetic Nephropathies; Disease Models, An | 2006 |
Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia.
Topics: Animals; Antibodies; Aorta, Abdominal; Arteriosclerosis; Blood Platelets; Cholesterol; Disease Model | 2000 |
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofib | 1988 |
[Strains and species differences in experimental hyperlipidemia].
Topics: Animals; Clofibrate; Disease Models, Animal; Gemfibrozil; Glycerides; Hyperlipidemias; Hypolipidemic | 1986 |